the serum calcium was increased by the oral administration of calcium carbonate, the decrement in serum i-PTH was only 25±6.65% when compared with 73.5±5.08% (P < 0.001) obtained by the administration of intravenous 1,25(OH)2D3. Thus, a similar serum calcium achieved by intravenous 1,25(OH)2D3 rather than calcium carbonate has a greater suppressive effect in the release of PTH.
Introduction
Secondary hyperparathyroidism is a universal complication of chronic renal insufficiency (1, 2) . Since parathyroid hormone (PTH)' acts upon the kidney to increase the production of 1,25(OH)2D3 (3) (4) (5) , which in turn increases intestinal calcium absorption, it seems possible that a negative feedback system could operate to regulate PTH secretion. In severe renal insufficiency the lack of 1,25(OH)2D3 could thus be a factor in maintaining the hypersecretion of PTH. There is substantial evidence that treatment with 1,25(OH)2D3 in chronic renal disease may result in severe hypercalcemia and consequent suppression of PTH secretion (6) . However, if hypercalcemia does not occur, PTH levels do not change. Since the parathyroid glands possess specific receptors for 1,25(OH)2D3 (7) and a calcium binding protein (8) , there is considerable interest in whether 1,25(OH)2D3 per se, independent of hypercalcemia, may play a role in the regulation of PTH secretion. To date, this issue remains controversial (9) (10) (11) (12) (13) (14) (15) .
Because recent studies have shown substantial degradation of 1,25(OH)2D3 in the intestine (16) , we reasoned that while oral administration of 1,25(OH)2D3 may inrease intestinal calcium absorption, the degradation of the vitamin D metabolite may impair the delivery of 1,25(OH)2D3 to other peripheral target organs and thus limit the expression of direct biological effects.
Accordingly, the present studies were designed to examine the effects of orally and intravenously administered 1,25(OH)2D3 on the levels of 1,25(OH)2D3 achieved in plasma and the effects of these therapies on PTH secretion. Methods 20 hypocalcemic patients, 9 females and 11 males, who underwent dialysis 4 h per session, three times per week using a hollow fiber dialyzer were selected for study. Residual creatinine clearance was <1 ml/min in all patients. The age ranged from 21 to 67 yr. Nine patients had nephrosclerosis, six had diabetes mellitus, three had polycystic kidneys, one had medullary cystic disease and another, pyelonephritis. Written consent was obtained in all patients and the research protocol was approved by the Human Studies Committee of Washington University. The study was of 9.0±0.3 mg/100 ml. Similar changes were observed in ionized calcium. During the control period mean ICa was 4.1±0.1 mg/100 ml, it increased to 4.8±0.1 mg/100 ml (peak response 5.4±0.1 mg/100 ml) during 1,25(OH)2D3 treatment, and decreased to 4.2±0.1 mg/100 ml after 1,25(OH)2D3 was discontinued.
In general, serum phosphorus tended to increase during 1,25(OH)2D3 administration. Thus, the amount of phosphatebinders administered to the patients was adjusted to maintain the levels of serum phosphorus relatively constant. Serum magnesium did not change during the entire study in all 20 patients.
The percent changes in the values for serum i-PTH are illustrated in Fig. 3 . In all patients there was a substantial decrease in the levels of i-PTH during intravenous 1,25(OH)2D3 treatment with a mean decrement of 70.1±3.2% (P < 0.001). After 1,25(OH)2D3 was discontinued i-PTH increased in all patients. mild secondary hyperparathyroidism. An 86% decrease in the levels of i-PTH was observed. After 1,25(OH)2D3 was discontinued, i-PTH rose to pretreatment levels. The temporal relationship between ionized calcium and serum i-PTH, in a group of six patients with moderate secondary hyperparathyroidism, is depicted in Fig. 5 (Fig. 7 ). There was a significant correlation (P < 0.001) between the increase in ionized calcium and the decrease in i-PTH, illustrating the crucial role of calcium in the suppression of PTH. However, at 0 increment in ionized calcium the regression line intercepted the ordinate at 80% of the original value, suggesting that in addition to the marked suppressive effect of calcium on PTH, 1,25(OH)2D3, per se, also affected the release of PTH in uremic patients.
Long-term studies of intravenous calcitriol administration. To determine if the suppression of i-PTH induced by the intravenous administration of 1,25(OH)2D3 was a temporary event, long-term studies were performed. Two patients with severe secondary hyperparathyroidism were selected for this study. Fig. 8 illustrates the results in one of the patients.
During the control period i-PTH averaged 316±9.1 gleq/ml. given to the dogs, the parathyroid glands appeared to be more sensitive to mild increments in serum calcium. It is known that parathyroid glands obtained from uremic patients have a shift in the set point for calcium suppression of PTH release (19, 20) . A higher concentration of ionized calcium than normal is required to suppress PTH release in secondary hyperparathyroidism. The set point for calcium is defined as the amount of calcium necessary to suppress 50% the release of PTH. Brown and collaborators (19, 20) working with normal dispersed human parathyroid cells found a set point for PTH release at a calcium concentration of 0.97±0.04 mM, but in patients with secondary hyperparathyroidism the set point was increased to 1 to peripheral tissues such as the parathyroid glands and allow for expression of biological effects at these sites. Regardless of the mechanism of action, the main implication of these studies is the impressive clinical utility of the intravenous 1,25(OH)2D3 in dialysis patients. 1,25(OH)2D3 can be easily given intravenously at the end of each dialysis. The patient's compliance is assured and for the first time this study showed a significant decrease in the levels of i-PTH in all 20 patients studied. A "medical parathyroidectomy" can now be easily accomplished.
